Emergent Biosolutions Inc
$ 8.07
-4.38%
05 Jun - close price
- Market Cap 416,382,000 USD
- Current Price $ 8.07
- High / Low $ 8.51 / 7.95
- Stock P/E N/A
- Book Value 10.10
- EPS -0.19
- Next Earning Report 2026-08-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.03 %
- ROE -0.02 %
- 52 Week High 14.06
- 52 Week Low 5.62
About
Emergent BioSolutions Inc., a life sciences company, focuses on providing preparedness and response products and solutions for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHT). The company is headquartered in Gaithersburg, Maryland.
Analyst Target Price
$12.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-30 | 2026-02-26 | 2025-10-29 | 2025-08-06 | 2025-05-07 | 2025-03-03 | 2024-11-06 | 2024-08-06 | 2024-05-01 | 2024-03-06 | 2023-11-07 | 2023-08-08 |
| Reported EPS | 0.21 | -0.43 | 1.06 | 0.16 | 0.71 | -0.5775 | 1.37 | -2.32 | 0.59 | -0.77 | -5.08 | -1.06 |
| Estimated EPS | -0.25 | 0.425 | -0.12 | -0.49 | 0.44 | -0.4957 | 0.14 | -0.97 | -0.83 | -0.19 | -0.54 | -0.62 |
| Surprise | 0.46 | -0.855 | 1.18 | 0.65 | 0.27 | -0.0818 | 1.23 | -1.35 | 1.42 | -0.58 | -4.54 | -0.44 |
| Surprise Percentage | 184% | -201.1765% | 983.3333% | 132.6531% | 61.3636% | -16.5019% | 878.5714% | -139.1753% | 171.0843% | -305.2632% | -840.7407% | -70.9677% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-05 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 0.11 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | |
|---|---|
| Payment Date | None |
| Amount | $1.855 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: EBS
2026-06-05 00:38:59
Emergent BioSolutions is partnering with Victoria’s Voice Foundation for National Naloxone Awareness Day to combat the opioid epidemic. The initiative focuses on increasing awareness and access to NARCAN® Nasal Spray through campaigns like "Shine. Wear. Share. Care." and the "Ready to Rescue" program. Both organizations emphasize the critical role of naloxone education and availability in saving lives and addressing the ongoing crisis.
2026-06-04 12:39:43
Emergent BioSolutions is partnering with Victoria’s Voice Foundation to support National Naloxone Awareness Day, aiming to combat the opioid epidemic by increasing awareness and access to NARCAN® Nasal Spray. The collaboration includes continuing the "Shine. Wear. Share. Care." campaign, distributing educational materials, and involving spokesperson Zac Clark to reach college communities. This initiative underscores the critical role of naloxone in overdose reversal and aligns with national efforts to expand access to life-saving tools.
2026-05-28 20:06:11
Emergent BioSolutions Inc. has been awarded a $64.5 million contract modification from the Administration for Strategic Preparedness and Response (ASPR) for its BAT® botulism antitoxin. This modification extends an existing 10-year contract and reinforces Emergent's role in supporting U.S. biodefense priorities by supplying critical medical countermeasures. The BAT® antitoxin treats symptomatic botulism after exposure to various botulinum neurotoxin serotypes in both adults and pediatric patients.
2026-05-28 20:06:11
Emergent BioSolutions Inc. has secured a $64.5 million contract modification for its anthrax treatment, BAT®, to bolster the U.S. biodefense strategy. This announcement highlights the company's continued role in public health preparedness against accidental, deliberate, and naturally occurring threats. Further news indicates recent approvals in Saudi Arabia and Singapore for its smallpox and mpox vaccines, along with new manufacturing agreements.
2026-05-28 20:04:11
Emergent BioSolutions (EBS) has secured a $64.5 million contract modification for its Anthrax Immune Globulin Intravenous (Human) (BAT®) product. This modification is intended to bolster the U.S. biodefense strategy, indicating continued government investment in preparedness against biological threats. The contract reinforces Emergent Biosolutions' role in providing critical medical countermeasures.
2026-05-28 20:02:11
Emergent BioSolutions Inc. has secured a $64.5 million contract modification from the U.S. Department of Health and Human Services for its botulism antitoxin, BAT®. This contract ensures the continued supply of BAT®, vital for treating symptomatic botulism, to support U.S. biodefense and preparedness efforts. The company leverages its North American supply chain to deliver this critical medical countermeasure for both military and civilian populations.
